Vivimed Labs (NSE:VIVIMEDLAB) Total Current Liabilities: ₹0.0 Mil (As of Dec. 2025)


NSE:VIVIMEDLAB Vivimed Labs Ltd NSE:VIVIMEDLAB
38 GF Score
Price ₹5.80
GF Value ₹2.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Vivimed Labs Total Current Liabilities?

Vivimed Labs NSE:VIVIMEDLAB -3.17% 38 Total Current Liabilities is ₹0.0 Mil as of Dec. 2025. GuruFocus rates NSE:VIVIMEDLAB with a GF Score™ of 38/100 and a GF Value™ of ₹2.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Vivimed Labs's total current liabilities for the quarter that ended in Dec. 2025 was ₹0.0

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Vivimed Labs Total Current Liabilities Related Terms

Vivimed Labs Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vivimed Labs's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivimed Labs Total Current Liabilities Chart

Vivimed Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,410.75 3,733.92 4,240.91 4,103.26 4,081.98

Vivimed Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4,081.98 0.00 4,346.01 0.00
NSE:VIVIMEDLAB
38GF Score
Vivimed Labs Ltd NSE:VIVIMEDLAB
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivimed Labs Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Vivimed Labs's Total Current Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=505.48+3127.13
+Other Current Liabilities+Current Deferred Liabilities
=449.37+0
=4,082.0

Vivimed Labs's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=0.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of ₹0.0 Mil mean?
Vivimed Labs (NSE:VIVIMEDLAB) has a Total Current Liabilities of ₹0.0 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vivimed Labs and its competitors.
Is Vivimed Labs' Total Current Liabilities too high?
Vivimed Labs' current Total Current Liabilities is ₹0.0 Mil. Overall, Vivimed Labs has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vivimed Labs' Total Current Liabilities compare to ZTS and UTHR?
Vivimed Labs' Total Current Liabilities of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Vivimed Labs and its competitors. Vivimed Labs's current Total Current Liabilities is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivimed Labs stock overvalued right now?
Based on GuruFocus' analysis, Vivimed Labs (NSE:VIVIMEDLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.56, compared to a current price of ₹5.80 — trading 126.6% above its estimated fair value. The current Total Current Liabilities is ₹0.0 Mil. Vivimed Labs' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Vivimed Labs (NSE:VIVIMEDLAB), the current Total Current Liabilities is ₹0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivimed Labs (NSE:VIVIMEDLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Vivimed Labs stock appears to be overvalued. The current stock price of ₹5.80 is trading 126.6% above its estimated GF Value™ of ₹2.56. GuruFocus considers Vivimed Labs to be Significantly Overvalued.

Key valuation signals for NSE:VIVIMEDLAB:

  • Total Current Liabilities: ₹0.0 Mil
  • GF Value™: ₹2.56 vs. price of ₹5.80 (126.6% above fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the NSE:VIVIMEDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivimed Labs Business Description

Other Exchanges 532660:India
Address Green Lands, Beside The Plaza Hotel, D.No. 6-3-866/1/G1, 3rd & 4th Floor, GMR Towers, Begumpet, Hyderabad, TG, IND, 500016
Vivimed Labs Ltd is an India-based company that is engaged in the Business of Active pharmaceutical ingredients, Intermediates, Nutraceutical ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals, and Retail Branded Formulation manufacturing. The company has three reportable segments: the Speciality Chemicals Business, the Pharma Business, and others. The majority of revenue is earned through the Pharma business.
38GF Score

Get the complete analysis for NSE:VIVIMEDLAB

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹5.80
Price
₹2.56
GF Value